CD19 and acute lymphoblastic leukemia: We previously described a dual-targeted therapy composed of CD19+ and CD22+ CAR-T cell cocktail, which has yielded a 93.3% CR rate in R/R B-cell acute lymphoblastic leukemia (B-ALL) and could reduce the risk of CD19− relapse reported previously [16].